The Management of Type 2 Diabetes Mellitus FOCUS on Quality

Primary Care - Clinics in Office Practice

Volumn 34, Issue 1, 2007, Pages 1-38

  Miser, William F ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; CHLORPROPAMIDE; EXENDIN 4; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLIMEPIRIDE; GLIMEPIRIDE PLUS ROSIGLITAZONE; GLIPIZIDE; GLIPIZIDE PLUS METFORMIN; INSULIN; INSULIN ASPART; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; METFORMIN PLUS PIOGLITAZONE; METFORMIN PLUS ROSIGLITAZONE; MIGLITOL; NATEGLINIDE; NOVOLIN R; PIOGLITAZONE; PRAMLINTIDE; REPAGLINIDE; RIOMET; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TOLAZAMIDE; TOLBUTAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL CRAMP; ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ACUTE PYELONEPHRITIS; ADD ON THERAPY; ANEMIA; ANOREXIA; BLOOD PRESSURE REGULATION; CELLULITIS; CHOLECYSTITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYANOCOBALAMIN DEFICIENCY; DEPRESSION; DIABETES EDUCATION; DIABETIC FOOT; DIABETIC KETOACIDOSIS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIARRHEA; DIET THERAPY; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; EMPHYSEMATOUS CHOLECYSTITIS; ERYTHEMA MULTIFORME; ERYTHEMA NODOSUM; EXFOLIATIVE DERMATITIS; EYE CARE; FLATULENCE; FLUID RETENTION; FOOT CARE; GENITAL CANDIDIASIS; GLUCOSE TOLERANCE; HEADACHE; HEALTH CARE QUALITY; HEARTBURN; HEPATITIS; HUMAN; HYPOGLYCEMIA; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; JAUNDICE; KIDNEY PAPILLA NECROSIS; LACTIC ACIDOSIS; LIVER FAILURE; LIVER FUNCTION TEST; LIVER TOXICITY; META ANALYSIS; METALLIC TASTE; MONOTHERAPY; MORBIDITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONKETOTIC DIABETIC COMA; OBSTRUCTIVE JAUNDICE; PATIENT EDUCATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHOTOSENSITIVITY; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; PURPURA; RASH; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SCREENING; SELF CARE; SIDE EFFECT; SINUSITIS; SMOKING CESSATION; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW; TASTE DISORDER; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIET; DRUG THERAPY, COMBINATION; EYE DISEASES; HEALTH SERVICES ACCESSIBILITY; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MOTOR ACTIVITY; PATIENT EDUCATION; PRIMARY HEALTH CARE; QUALITY OF HEALTH CARE; RISK FACTORS; SMOKING CESSATION;

EID: 34247634610     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pop.2007.01.001     Document Type: Review

References (170)

1. Rosenblatt R.A., Baldwin L.M., Chan L., et al. Improving the quality of outpatient care for older patients with diabetes: lessons from a comparison of rural and urban communities. J Fam Pract 50 8 (2001) 676-680
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 27 Suppl 1 (2006) S43-S48
3. McKinlay J., and Marceau L. US public health and the 21st century: diabetes mellitus. Lancet 356 (2000) 757-761
4. Barr R., Nathan D., Meigs J., et al. Tests of glycemia for the diagnosis of type 2 diabetes mellitus. Ann Intern Med 137 (2002) 263-272
5. American Diabetes Association. Tests of glycemia in diabetes. Diabetes Care 26 Suppl 1 (2003) S106-S108
6. Engelgau M., Thompson T., Herman W., et al. Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes: diagnostic criteria and performance revisited. Diabetes Care 20 5 (1997) 785-791
7. Rose E., Ketchell D., and Markova T. Clinical inquiries: does daily monitoring of blood glucose predict hemoglobin A1c levels?. J Fam Pract 52 6 (2003) 485-490
8. Groop L. Pathogenesis of type 2 diabetes: the relative contribution of insulin resistance and impaired insulin secretion. Int J Clin Pract Suppl 113 (2000) 3-13
9. Goldstein B.J. Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol 90 5A (2002) 3G-10G
10. Aye T., and Levitsky L. Type 2 diabetes: an epidemic disease in childhood. Curr Opin Pediatr 15 (2003) 411-415
11. Liese A.D., D'Agostino Jr. R.B., Hamman R.F., et al. The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics 118 4 (2006) 1510-1518
12. Hosszufalusi N., Vatay A., Rajczy K., et al. Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression. Diabetes Care 26 2 (2003) 452-457
13. Palmer J.P., and Hirsch I.B. What's in a name: latent autoimmune diabetes of adults, type 1.5, adult-onset, and type 1 diabetes. Diabetes Care 26 2 (2003) 536-538
14. Pozzilli P., and Di Mario U. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention. Diabetes Care 24 8 (2001) 1460-1467
15. Rosario P.W., Reis J.S., Amim R., et al. Comparison of clinical and laboratory characteristics between adult-onset type 1 diabetes and latent autoimmune diabetes in adults. Diabetes Care 28 7 (2005) 1803-1804
16. Fuller J.H., Shipley M.J., Rose G., et al. Coronary-heart-disease risk and impaired glucose tolerance: the Whitehall study. Lancet 1 8183 (1980) 1373-1376
17. Harris M.I., Flegal K.M., Cowie C.C., et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: the Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 21 4 (1998) 518-524
18. The Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle changes. Diabetes Care 25 (2002) 2165-2171
19. The Diabetes Prevention Program (DPP) Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
20. Rubin R.R., Fujimoto W.Y., Marrero D.G., et al. The Diabetes Prevention Program: recruitment methods and results. Control Clin Trials 23 2 (2002) 157-171
21. American Diabetes Association National Institute of Diabetes. Digestive and kidney diseases: the prevention or delay of type 2 diabetes. Diabetes Care 26 Suppl 1 (2003) S62-S69
22. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 6 (2002) 393-403
23. Rao S., Kakkar S., Wilder L., et al. Clinical inquiries: what is the best strategy for impaired glucose tolerance in nonpregnant adults?. J Fam Pract 54 6 (2005) 543-544
24. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 27 Suppl 1 (2004) S11-S14
25. rd edition. Rockville (MD): US Preventive Services Task Force. Available at: www.ahrq.gov/clinic/3rduspstf/diabscr/diabetrr.htm. Accessed September 27, 2006.
26. National Institute of Diabetes and Digestive and Kidney Diseases. National diabetes statistics fact sheet: general information and national estimates of diabetes in the United States, 2005 (2005), US Department of Health and Human Services, National Institute of Health, Bethesda (MD)
27. Nathan D.M. Long-term complications of diabetes mellitus. N Engl J Med 328 23 (1993) 1676-1685
28. Clark Jr. C.M., and Lee D.A. Prevention and treatment of the complications of diabetes mellitus. N Engl J Med 332 18 (1995) 1210-1217
29. Frank R. Diabetic retinopathy. N Engl J Med 332 (2004) 1210-1217
30. Remuzzi G., Schieppati A., and Ruggenenti P. Nephropathy in patients with type 2 diabetes. N Engl J Med 346 (2002) 1145-1151
31. Wilson P.W., and Kannel W.B. Obesity, diabetes, and risk of cardiovascular disease in the elderly. Am J Geriatr Cardiol 11 2 (2002) 119-123
32. Selvin E., Marinopoulos S., Berkenblit G., et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141 (2004) 421-431
33. Black S.A. Diabetes, diversity, and disparity: what do we do with the evidence?. Am J Public Health 92 4 (2002) 543-548
34. American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care 26 (2003) 917-932
35. Gilmer T.P., O'Connor P.J., Manning W.G., et al. The cost to health plans of poor glycemic control. Diabetes Care 20 12 (1997) 1847-1853
36. Harris M.I., Eastman R.C., Cowie C.C., et al. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 22 3 (1999) 403-408
37. Carter J.S., Pugh J.A., and Monterrosa A. Non-insulin-dependent diabetes mellitus in minorities in the United States. Ann Intern Med 125 3 (1996) 221-232
38. Gaillard T.R., Schuster D.P., Bossetti B.M., et al. Do sociodemographics and economic status predict risks for type II diabetes in African Americans?. Diabetes Educ 23 3 (1997) 294-300
39. Wisdom K., Fryzek J.P., Havstad S.L., et al. Comparison of laboratory test frequency and test results between African-Americans and Caucasians with diabetes: opportunity for improvement. Findings from a large urban health maintenance organization. Diabetes Care 20 6 (1997) 971-977
40. Schoenberg N.E., Amey C.H., and Coward R.T. Diabetes knowledge and sources of information among African American and white older women. Diabetes Educ 24 3 (1998) 319-324
41. Fiscella K., Franks P., Gold M.R., et al. Inequality in quality: addressing socioeconomic, racial, and ethnic disparities in health care. JAMA 283 19 (2000) 2579-2584
42. Connolly V.M., and Kesson C.M. Socioeconomic status and clustering of cardiovascular disease risk factors in diabetic patients. Diabetes Care 19 5 (1996) 419-422
43. Robinson N., Lloyd C.E., and Stevens L.K. Social deprivation and mortality in adults with diabetes mellitus. Diabet Med 15 3 (1998) 205-212
44. Beckles G., and Thompson-Reid P. Socioeconomic status of women with diabetes: United States, 2000. MMWR MOrb Mortal Wkly Rep 51 (2002) 147-148
45. Wong M.D., Shapiro M.F., Boscardin W.J., et al. Contribution of major diseases to disparities in mortality. N Engl J Med 347 20 (2002) 1585-1592
46. National Institutes of Health. Strategic research plan to reduce and ultimately eliminate health disparities (2000), US Department of Health and Human Services, Bethesda (MD)
47. American Diabetes Association. Hyperglycemic crises in patients with diabetes mellitus. Diabetes Care 26 Suppl 1 (2003) S109-S117
48. Trence D.L., and Hirsch I.B. Hyperglycemic crises in diabetes mellitus type 2. Endocrinol Metab Clin North Am 30 4 (2001) 817-831
49. Delaney M.F., Zisman A., and Kettyle W.M. Diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome. Endocrinol Metab Clin North Am 29 4 (2000) 683-705
50. American Diabetes Association. Hypoglycemia and employment/licensure. Diabetes Care 28 Suppl 1 (2006) S61
51. Herbel G., and Boyle P.J. Hypoglycemia: pathophysiology and treatment. Endocrinol Metab Clin North Am 29 4 (2000) 725-743
52. McAulay V., Deary I.J., and Frier B.M. Symptoms of hypoglycaemia in people with diabetes. Diabet Med 18 9 (2001) 690-705
53. Cefalu C.A., and Cefalu W.T. Controlling hypoglycemia in type 2 diabetes: which agent for which patient?. J Fam Pract 54 10 (2005) 855-862
54. American Diabetes Association. Immunization and the prevention of influenza and pneumococcal disease in people with diabetes. Diabetes Care 26 Suppl 1 (2003) S126-S128
55. Gaba M.K., Gaba S., and Clark L.T. Cardiovascular disease in patients with diabetes: clinical considerations. J Assoc Acad Minor Phys 10 1 (1999) 15-22
56. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 26 Suppl 1 (2003) S83-S86
57. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 26 Suppl 1 (2003) S80-S82
58. Taskinen M.R. Diabetic dyslipidemia. Atheroscler Suppl 3 1 (2002) 47-51
59. American Diabetes Association. Smoking and diabetes. Diabetes Care 26 Suppl 1 (2003) S89-S91
60. Carman T.L., and Fernandez Jr. B.B. A primary care approach to the patient with claudication. Am Fam Physician 61 4 (2000) 1027-1032
61. Fong D.S., Aiello L., Gardner T.W., et al. Diabetic retinopathy. Diabetes Care 26 1 (2003) 226-229
62. American Diabetes Association. Diabetic nephropathy. Diabetes Care 26 Suppl 1 (2003) S94-S98
63. Skyler J.S. Microvascular complications. Retinopathy and nephropathy. Endocrinol Metab Clin North Am 30 4 (2001) 833-856
64. Simmons Z., and Feldman E.L. Update on diabetic neuropathy. Curr Opin Neurol 15 5 (2002) 595-603
65. Boulton A., Vinik A., Abezzo J., et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 28 4 (2005) 956-962
66. Aring A., Jones D., and Falko J. Evaluation and prevention of diabetic neuropathy. Am Fam Physician 71 11 (2005) 2123-2128
67. Armstrong D.G., and Lavery L.A. Diabetic foot ulcers: prevention, diagnosis and classification. Am Fam Physician 57 6 (1998) 1325-1332
68. Singh N., Armstrong D.G., and Lipsky B.A. Preventing foot ulcers in patients with diabetes. JAMA 293 2 (2005) 217-228
69. American Diabetes Association. Preventive foot care in people with diabetes. Diabetes Care 26 Suppl 1 (2003) S78-S79
70. Goldney R., Phillips P., Fisher L., et al. Diabetes, depression, and quality of life: a population study. Diabetes Care 27 (2004) 1066-1070
71. Katon W., Rutter C., Simon G., et al. The association of comorbid depression with mortality in patients with type 2 diabetes. Diabetes Care 28 (2005) 2668-2672
72. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
73. The Diabetes Control and Complicatoins Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
74. UK Prospective Diabetes Study (UKPDS). Study design, progress and performance. Diabetologia 34 12 (1991) 877-890
75. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 7258 (2000) 405-412
76. Eastman R.C., Javitt J.C., Herman W.H., et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 20 5 (1997) 735-744
77. Menzin J., Langley-Hawthorne C., Friedman M., et al. Potential short-term economic benefits of improved glycemic control: a managed care perspective. Diabetes Care 24 1 (2001) 51-55
78. Hunt L.M., Pugh J., and Valenzuela M. How patients adapt diabetes self-care recommendations in everyday life. J Fam Pract 46 3 (1998) 207-215
79. Freeman J., and Loewe R. Barriers to communication about diabetes mellitus: patients' and physicians' different view of the disease. J Fam Pract 49 6 (2000) 507-512
80. Mensing C., Boucher J., Cypress M., et al. National standards for diabetes self-management education. Diabetes Care 29 Suppl 1 (2006) S78-S85
81. American Diabetes Association. Evidence-based nutrition principles and recommendations for the treatment of diabetes and related complications. Diabetes Care 26 Suppl 1 (2003) S51-S61
82. American Diabetes Association. Physical activity/exercise and diabetes mellitus. Diabetes Care 26 Suppl 1 (2003) S73-S77
83. Ho P.M., Rumsfeld J.S., Masoudi F.A., et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 166 17 (2006) 1836-1841
84. Deakin T., McShane C.E., Cade J.E., et al. Group based training for self-management strategies in people with type 2 diabetes mellitus. Cochrane Database Syst Rev 2 (2005) CD003417
85. Bodenheimer T., Wagner E., and Grumbach K. Improving primary care for patients with chronic illness. JAMA 288 (2002) 1775-1779
86. Paasche-Orlow M., Parker R., Gazmararian J., et al. The prevalence of limited health literacy. J Gen Intern Med 20 (2004) 175-184
87. Moore H., Summerbell C., Hooper L., et al. Dietary advice for treatment of type 2 diabetes mellitus in adults. Cochrane Database Syst Rev 3 (2004) CD004097
88. Geil P., and Leontos C. Nutrition practice guideline care improves diabetes outcomes. Diabetes Spectrum 17 2 (2004) 83-86
89. Thomas D.E., Elliott E.J., and Naughton G.A. Exercise for type 2 diabetes mellitus. Cochrane Database Syst Rev 3 (2006) CD002968
90. Gregg E., Gerzoff R., and Caspersen C. Relationship of walking to mortality among US adults with diabetes. Arch Intern Med 163 (2003) 1440-1447
91. Gibbons R.J., Balady G.J., Bricker J.T., et al. ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to update the 1997 exercise testing guidelines). Circulation 106 14 (2002) 1883-1892
92. Piette J., Heisler M., and Wagner T. Cost-related medication underuse: do patients with chronic illnesses tell their doctors?. Arch Intern Med 164 (2004) 1749-1755
93. Inzucchi S.E. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 287 3 (2002) 360-372
94. Sami T., Kabadi U.M., and Moshiri S. The effect on metabolic control of second-generation sulfonylurea drugs in patients with NIDDM after secondary failure to first-generation agents. J Fam Pract 43 4 (1996) 370-374
95. Metformin for non-insulin-dependent diabetes mellitus. Med Lett Drugs Ther 37 948 (1995) 41-42
96. Acarbose for diabetes mellitus. Med Lett Drugs Ther 38 967 (1996) 9-10
97. Miglitol for type 2 diabetes mellitus. Med Lett Drugs Ther 41 1053 (1999) 49-50
98. Repaglinide for type 2 diabetes mellitus. Med Lett Drugs Ther 40 1027 (1998) 55-56
99. Pioglitazone (Actos). Med Lett Drugs Ther 41 1066 (1999) 112
100. Rosiglitazone for type 2 diabetes mellitus. Med Lett Drugs Ther 41 1059 (1999) 71-73
101. Exenatide (Byetta) for type 2 diabetes. Med Lett Drugs Ther 47 1210 (2005) 45-46
102. Pramlintide (Symlin) for diabetes. Med Lett Drugs Ther 47 1209 (2005) 43-44
103. Ting R.Z., Szeto C.C., Chan M.H., et al. Risk factors of vitamin B12 deficiency in patients receiving metformin. Arch Intern Med 166 18 (2006) 1975-1979
104. Salpeer S., Greber E., Pasternak G., et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 1 (2006) CD002967
105. Charbonnel B., Dormandy J., and Erdmann E. The prospective pioglitazone clinical trial in macrovascular events (PROactive). Diabetes Care 27 (2004) 1647-1653
106. Basken S., Neher J., and Dodson S. TZDs increase the risk of heart failure for patients with diabetes. J Fam Pract 54 8 (2005) 723-724
107. Isley W.L. Review: alpha-glucosidase inhibitors improve glycemic control but have uncertain effects on patient-important outcomes in type 2 diabetes. ACP J Club 143 3 (2005) 66
108. Salehi M., and D'Alessio D.A. New therapies for type 2 diabetes based on glucagon-like peptide 1. Cleve Clin J Med 73 4 (2006) 382-389
109. Hoogwerf R.J. Exenatide and pramlintide: new glucose-lowering agents for treating diabetes mellitus. Cleve Clin J Med 73 5 (2006) 477-484
110. LeRoith D., Levetan C.S., Hirsch I.B., et al. Type 2 diabetes: the role of basal insulin therapy. J Fam Pract 53 3 (2004) 215-222
111. DeWitt D., and Hirsch I. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: a scientific review. JAMA 289 17 (2003) 2254-2264
112. Sutherland J., and Hoehns J. Treating type 2 diabetes: targeting the causative factors. J Fam Pract 53 5 (2004) 376-388
113. American Diabetes Association. Insulin administration. Diabetes Care 26 Suppl 1 (2003) S121-S124
114. Turner R.C., Cull C.A., Frighi V., et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281 21 (1999) 2005-2012
115. Elasy T.A., Levy P., and Davis S.N. Optimizing combination therapy for type 2 diabetes in adolescents and adults: a case-based approach. J Fam Pract 53 10 (2004) 815-822
116. Saenz A., Hernandez-Esteban I., Matix A., et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 3 (2005) CD002966
117. American Diabetes Association. Standards of medical care in diabetes: 2006. Diabetes Care 29 Suppl 1 (2006) S4-S42
118. American Association of Clinical Endocrinologists. Medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management: 2000 update. Endocr Pract 8 Suppl 1 (2000) 40-82
119. Woolf S., Davidson M., Greenfield S., et al. Controlling blood glucose levels in patients with type 2 diabetes mellitus: an evidence-based policy statement by the American Academy of Family Physicians and American Diabetes Association. J Fam Pract 49 (2000) 453-460
120. Welschen L.M., Bloemendal E., Nijpels G., et al. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review. Diabetes Care 28 6 (2005) 1510-1517
121. Welschen L.M., Bloemendal E., Nijpels G., et al. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin. Cochrane Database Syst Rev 2 (2005) CD005060
122. Saaddine J., Cadwell B., Gregg E., et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med 144 (2006) 465-474
123. Saaddine J., Engelgau M., Beckles G., et al. A diabetes report card for the United States: quality of care in the 1990s. Ann Intern Med 136 (2002) 565-574
124. Bodenheimer T., Wagner E., and Grumbach K. Improving primary care for patients with chronic illness: the chronic care model (part 2). JAMA 288 (2002) 1909-1914
125. Platt G., Orchard T., Emerson S., et al. Translating the Chronic Care Model into the community. Results from a randomized controlled trial of a multifaceted diabetes care intervention. Diabetes Care 29 (2006) 811-817
126. Mayfield J.A., Reiber G.E., Nelson R.G., et al. Do foot examinations reduce the risk of diabetic amputation?. J Fam Pract 49 6 (2000) 499-504
127. Kruse I., and Edelman S. Evaluation and treatment of diabetic foot ulcers. Clinical Diabetes 24 2 (2006) 91-93
128. Farnsworth J., and Paulman P. Diabetic foot ulcer and poor compliance: how would you treat?. J Fam Pract 54 9 (2005) 768-776
129. Boulton A.J., Kirsner R.S., and Vileikyte L. Clinical practice: neuropathic diabetic foot ulcers. N Engl J Med 351 1 (2004) 48-55
130. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. BMJ 317 (1998) 703-713
131. Miller S., and Lindbloom E.J. What is a reasonable interval for retinopathy screening in patients with diabetes?. J Fam Pract 52 5 (2003) 357-359
132. Tubbs C.G., Safeek A., Mayo H.G., et al. Clinical inquiries: do routine eye exams reduce occurrence of blindness from type 2 diabetes?. J Fam Pract 53 9 (2004) 732-734
133. Hutchinson A., McIntosh A., Peters J., et al. Effectiveness of screening and monitoring tests for diabetic retinopathy-a systematic review. Diabet Med 17 7 (2000) 495-506
134. Younis N., Broadbent D.M., Vora J.P., et al. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet 361 9353 (2003) 195-200
135. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285 19 (2001) 2486-2497
136. Whiteley L., Padmanabhan S., Hole D., et al. Should diabetes be considered a coronary heart disease risk equivalent? Results from 25 years of follow-up in the Renfrew and Paisley survey. Diabetes Care 28 7 (2005) 1588-1593
137. Zandbergen A.A., Sijbrands E.J., Lamberts S.W., et al. Normotensive women with type 2 diabetes and microalbuminuria are at high risk for macrovascular disease. Diabetes Care 29 8 (2006) 1851-1855
138. Howard B., Best L., Galloway J., et al. Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care 29 2 (2006) 391-397
139. Turner R., Millns H., Neil H., et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316 (1998) 823-828
140. Huang E., Meigs J., and Singer D. The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am J Med 111 (2001) 633-642
141. Ullom-Minnich P. Strategies to reduce complications of type 2 diabetes. J Fam Pract 53 5 (2004) 366-375
142. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 6 (2003) 1206-1252
143. Konzem S.L., Devore V.S., and Bauer D.W. Controlling hypertension in patients with diabetes. Am Fam Physician 66 7 (2002) 1209-1214
144. Julius S., Majahalme S., and Palatini P. Antihypertensive treatment of patients with diabetes and hypertension. Am J Hypertens 14 11 Pt 2 (2001) 310S-316S
145. Niskanen L., Hedner T., Hansson L., et al. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic β-blocker-based treatment regimen: a subanalysis of the captopril prevention project. Diabetes Care 24 (2001) 2091-2096
146. Pyorala K., Pedersen T., Kjekshus J., et al. Cholesterol lowering with simvastatin improves prognnosis of diabetic patients with coronary heart disease:.a subgroup of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20 (1997) 614-620
147. The ALLHAT Collaborative Research Group. Major outcomes in modestly hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA 288 (2002) 2998-3007
148. Collins R., Armitage J., Parish S., et al. BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
149. Colhoun H., Betteridge D., Durrington P., et al. Primary prevention of cardiovascular disease with atorvastin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 364 9435 (2004) 685-696
150. Vijan S., and Hayward R. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med 140 (2004) 650-658
151. Snow V., Aronson M., Hornbake E., et al. Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 140 (2004) 644-649
152. Grundy S., Cleeman J., Merz C., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
153. Lo V., Noviasky J., and Nashelsky J. Statin therapy in patients with type 2 diabetes. Am Fam Physician 72 5 (2005) 866-868
154. Swever P., Dahlof B., Poulter N., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
155. Steering Committee of the Physician's Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 321 (1989) 129-135
156. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus: Early Treatment Diabetic Retinopathy Study report 14. JAMA 268 (1992) 1292-1300
157. Hansson L., Zanchetti A., Carruthers C., et al. Effects of intensive blood-pressure lowering and low dose aspirin on patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 351 (1998) 1755-1762
158. Miser W. An aspirin a day keeps the MI away (for some). Am Fam Physician 65 (2001) 2000-2001
159. American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 27 Suppl 1 (2004) S72-S73
160. Retnakaran R., Cull C., Thorne K., et al. Risk factors for renal dysfunction in type 2 diabetes: UK Prospective Diabetes Study 74. Diabetes 55 (2006) 1832-1839
161. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 Suppl 1 (2002) S1-266
162. Kramer H., and Molitch M. Screening for kidney disease in adults with diabetes. Diabetes Care 28 7 (2005) 1813-1816
163. Scheid D., McCarthy L., Lawler F., et al. Screening for microalbuminuria to prevent nephropathy in patients with diabetes: a systematic review of the evidence. J Fam Pract 50 8 (2001) 661-668
164. Wilson S. Does microalbuminuria screening in diabetes prevent complications?. J Fam Pract 52 3 (2003) 229-231
165. Strippoli G., Craig M., and Craig J. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev 4 (2005) CD004136
166. Sferra L., Kelsberg G., and Do Dodson S. ACE inhibitors prevent nephropathy in type 2 diabetes without proteinuria?. J Fam Pract 53 (2004) 68-69
167. Go A., Chertow G., Fan D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004) 1296-1305
168. Penmetsa S., and Simmons M. For those intolerant to ACE inhibitors and ARBs, what is the best therapy for reducing the risk of diabetic nephropathy?. J Fam Pract 54 8 (2005) 711-713
169. Backonja M., Beydoun A., Edwards K.R., et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 280 21 (1998) 1831-1836
170. Gilron I., and Flatters S.J. Gabapentin and pregabalin for the treatment of neuropathic pain: a review of laboratory and clinical evidence. Pain Res Manag 11 Suppl A (2006) 16A-29A